patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.
Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study.

Peripheral blood or bone marrow aspirate samples

Acute Myeloid Leukemia

Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).

flow cytometric immunophenotyping

Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.
The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes.

Xist gene by fluorescence insitu hybridization

Faculty of medicine

Immunophenotyping and Xist Gene in AML

Relationship Between Immunophenotyping and X-inactive Specific Transcript (Xist) Gene in Acute Myeloid Leukemia

Identify X- inactive specific transcript (Xist) gene by fluorescence insitu hybridization (FISH) in AML

Integrating multiple strategies by Identification through multiparametric flow cytometry atdiagnosis of an immunophenotypic fingerprint associated with Xist gene abnormalities, detected by FISH, as a novel and simplified tool with improved sensitivity, to detect these abnormalities may allowing patient stratification and risk adapted treatment with potential impact on outcome of the disease.

Alaa Mahmoud Ali Kassem

Assistant lecturer

Assiut University

stereotactic brain surgery of human stem cells (OK99)

Idiopathic Parkinson Disease

MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.
For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.
To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.
After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery.

Human Stem Cells

Procurement was performed according to NIH Guidelines

Hospital Angeles del Pedregal

Parkinsonian Brain Repair Using Human Stem Cells

Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease

Celavie Bioscences, LLC

30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient

Aneurysmal Subarachnoid Hemorrhage

30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage

erythropoietin beta

Department of Neurosurgery, Addenbrooke's Hospital

Erythropoietin Therapy for Subarachnoid Hemorrhage

Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage

vasculitis/tyrosine

Immunophenotyping and Xist Gene in AML

Parkinsonian Brain Repair Using Human Stem Cells

Erythropoietin Therapy for Subarachnoid Hemorrhage

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo